Clinical Trials on de Novo or Restenosis Lesions

Total 495 results

Abbott Medical Devices
Baim Institute for Clinical Research

Withdrawn

Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery (I-WIN)

With de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
Medinol Ltd.

Completed

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)

de Novo or Restenosis Lesions

Japan
Medinol Ltd.

Completed

NIRTRAKS Post-Market Study (NIRTRAKS) (NIRTRAKS)

de Novo Stenotic Lesions in Native Coronary Arteries

United States
Biotronik AG

Completed

First in Man Trial - BIOSOLVE-I (BIOSOLVE-I)

de Novo Lesions in Native Coronary Arteries

Netherlands, Switzerland, Germany, Belgium
Biotronik AG

Completed

Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice (ENERGY)

De Novo and Re-stenosed Coronary Artery Lesions

Switzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
Boston Scientific Corporation

Completed

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program (ARRIVE 2)

Cardiovascular Disease | de Novo Coronary Lesions

United States
Shenzhen People's Hospital

Not yet recruiting

Resting Full-cycle Ratio-guided Step by Step Balloon Dilation (REDUCE)

de Novo Coronary Lesions
University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar

Completed

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis (D2OBREATH)

De Novo Lipogenesis (DNL)

Switzerland
Novartis

Completed

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

de Novo Liver Transplantation

Germany, Italy, Switzerland
University Hospital, Tours
Astellas Pharma Inc

Unknown

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (ADEQUATE)

De Novo Transplant Disease

France
Biotronik AG

Terminated

BIOFLOW-SV All Comers Registry (BIOFLOW-SV)

Restenoses, Coronary | de Novo | Symptomatic Ischemic Heart Disease

Brazil
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

De Novo Kidney Transplant Recipients
Rigshospitalet, Denmark

Completed

Early Detection of de Novo Cancer in Liver Transplant Recipients (DETECT)

Liver Transplant Disorder | De Novo Cancer
China National Center for Cardiovascular Diseases

Recruiting

STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (STENTLESS)

De Novo Stenosis | Drug-coated Balloon | Drug-eluting Stent

China
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions (BOSS)

PCI | De Novo Stenosis | DCB

Italy
Novartis Pharmaceuticals

Completed

Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients

De Novo Renal Transplantation

Norway
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

De Novo Kidney Transplantation

Belgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
Novartis

Completed

Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients

De Novo Kidney Transplantation
Astellas Pharma Inc

Completed

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

De Novo Kidney Transplant Patients

China
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects (Maple)

de Novo Liver Transplant Subjects

Korea, Republic of
Erasmus Medical Center
Hoffmann-La Roche

Completed

Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation

De Novo Renal Transplant Recipient.

France, Spain, Taiwan, Denmark, Australia, United Kingdom, Germany, Canada, Belgium, China, Sweden, Netherlands, Austria, Brazil, Estonia, Lithuania, Norway, Poland, Venezuela
Advanced MedTech Solutions Pvt. Ltd.

Not yet recruiting

Advapro Coronary Stent System in Coronary Artery Diseased Patients. (RESTORE)

Coronary Artery Disease | Coronary Stent Implantation | De Novo Stenosis Lesion
University Hospital, Saarland

Terminated

Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™ (PEPCAD-DEBonly)

Coronary De-novo Stenoses

Germany
S.M. Misericordia Hospital

Completed

Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions (DESERT)

Stable Coronary Artery Disease | Silent Myocardial Ischemia | In-stent(BMS)Restenosis | De-novo, Atherosclerotic, Coronary Lesions

Italy
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis

Completed

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)

Renal Transplantation | de Novo Kidney Transplant Recipients

Italy
University Hospital, Tours
Astellas Pharma Inc

Unknown

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (ADEQUATEartère)

De Novo Transplant Disease

France
Zunyi Medical College

Recruiting

Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization

Acute Coronary Syndrome | De Novo Stenosis

China
Xijing Hospital

Recruiting

Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions (REC-CHIPCAC)

De Novo Stenosis | Severely Calcified Coronary Stenoses

China
Astellas Pharma Korea, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation (AdProCISE)

de Novo Kidney Transplantation

Korea, Republic of
Sydney South West Area Health Service

Unknown

IVUS Controlled Stenting

Coronary Angioplasty and Stenting | Single de Novo Coronary Artery Stenoses

Australia
Xijing Hospital

Active, not recruiting

Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions

Coronary Artery Disease | De Novo Stenosis

China
Novartis Pharmaceuticals

Completed

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

de Novo Heart Failure

United States
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...

Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Kidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies Development

United States
Tryton Medical, Inc.

Completed

Prospective, Single Blind, Rand Controlled Study to Evaluate the Safety & Effectness of Tryton Side Branch Stent Used With DES Treatmt of de Novo Bifurcation Lesions in MB & SB in Native Coronaries (TRYTON)

Coronary Atherosclerosis of Native Coronary Artery | Bifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary Artery

United States
Novartis Pharmaceuticals

Completed

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients (Spartacus)

Pharmacokinetics Study in de Novo Kidney Transplantation

Germany
Xijing Hospital

Active, not recruiting

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions (CAGE-FREEIII)

Coronary Artery Disease | Percutaneous Coronary Intervention | De Novo Stenosis

China
Genoss Co., Ltd.

Completed

Compare the Efficacy and Safety of Genoss® DCB and IN.PACT Admiral® DCB in Patients With Peripheral Artery Disease

Peripheral Artery Disease | De Novo Stenosis

Korea, Republic of
PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
Imperial College London Diabetes Centre

Unknown

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

Mendelian Disorders | Genetic Disorder | Novel Mutation | Hereditary Disorder | De Novo Mutation | Inherited Disease | Single-Gene Defects

United Arab Emirates
Novartis

Completed

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

De Novo Renal Transplantation
Korea University Ansan Hospital
B. Braun Korea Co., Ltd.

Recruiting

STabilization of Atheroma By Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB) (STABLE-DCB)

Coronary Artery Disease | De Novo Stenosis | Atherosclerotic Plaque

Korea, Republic of
B. Braun Medical Industries Sdn. Bhd.
Seoul National University Hospital; Ulsan University Hospital; European Cardiovascular... and other collaborators

Recruiting

Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease (REVERSE)

Myocardial Ischemia | Coronary Artery Disease | Acute Coronary Syndrome | Coronary Stenosis | De Novo Stenosis

Malaysia, Taiwan, Korea, Republic of, Singapore
Yinyi(Liaoning) Biotech Co., Ltd.

Completed

Bingo Drug-Coated Balloon in Real World

Coronary Stenosis | De Novo Stenosis | Drug-coated Balloon | Coronary Artery Disease in Transplanted Heart Accelerated

China
General Administration of Military Health, Tunisia
B. Braun Medical International Trading Company Ltd.

Recruiting

Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent (DEBATE)

Coronary Artery Disease (CAD) | De Novo Stenosis | Percutaneous Coronary Intervention (PCI)

Tunisia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial. (HighCPAP)

De Novo Hypoxemic Acute Respiratory Failure (hARF)
Tel-Aviv Sourasky Medical Center

Completed

CRE8 in All Comers Patients

Consecutive Subjects Who Are Suitable for a Coronary | Angioplasty of de Novo Lesion(s) in Native Coronary | Arteries Should be Screened for Eligibility. | A Total Number of 200 Patients Fulfilling the Selection | Criteria and Willing to Sign the Informed Consent Should | be Enrolled in the...

Israel
Seoul National University Hospital

Unknown

Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

In-stent Restenosis Lesion

Korea, Republic of

Clinical Trials on de Novo or Restenosis Lesions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations